Apparently not. This article (http://www.telegraph.co.uk/finance/newsbysector/pharmaceutic...) suggests its a case of economics. That is new antibiotics would be kept back as a last line of defence only; therefore not as profitable.
We spend tax money on defense because it's a public good and in the absence of tax dollars there's no money in it. The same applies here.